TrialBMC medicine2022

Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial.

Zhengbo Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.